Related Experiment Video

Updated: May 29, 2026

Cell-Specific Paired Interrogation of the Mouse Ovarian Epigenome and Transcriptome
12:25

Cell-Specific Paired Interrogation of the Mouse Ovarian Epigenome and Transcriptome

Published on: February 24, 2023

Multi-omics pleiotropic association analyses reveal functionally relevant genes and druggable pathways for ovarian

Xuan Lian1,2, Shuang Song3,4,5,6, Chen Lou2

  • 1Reproductive Medicine Center, Zhongshan Hospital, Fudan University, Shanghai, China.

Genome Biology
|May 28, 2026
PubMed
Abstract

Insights

Ovarian aging, a decline in egg quality and number, is poorly understood. Targeting DNA repair via PD-L1 blockade shows promise for delaying ovarian aging and preserving fertility.

Area of Science:

  • Reproductive biology
  • Genetics
  • Molecular biology

Background:

  • Ovarian aging involves decreased oocyte quantity and quality, impacting female reproduction.
  • The underlying biological mechanisms of ovarian aging are not well understood.
  • Current therapeutic options for ovarian aging are limited.

Purpose of the Study:

  • To identify molecular traits associated with ovarian aging.
  • To explore potential therapeutic targets for delaying ovarian aging.

Main Methods:

  • Integrative analysis of multi-omics data and genome-wide association studies.
  • Mendelian randomization and cross-omics association approaches.
  • Experimental validation of identified targets.

Main Results:

  • Prioritized key proteins, gene expressions, splicing events, and metabolites linked to ovarian aging.
  • Identified conserved genes across species and cell types.
  • Highlighted the mismatch repair gene MSH6 (MutS Homolog 6) as a key candidate.
  • Experimental validation suggested targeting DNA repair through PD-L1 (Programmed Death-Ligand 1) blockade.

Conclusions:

  • Uncovered the complex genetic and molecular basis of ovarian aging.
  • Identified molecular traits offering potential for functional studies.
  • Suggested novel therapeutic strategies for preserving ovarian function and mitigating age-related decline.
Keywords:
DNA repairMSH6Mendelian randomizationMulti-omicsOvarian agingPD-L1

More Related Videos

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Genomics02:02

Genomics

Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...